Attenuating Aβ1-42-induced toxicity by a novel acetylcholinesterase inhibitor

Neuroscience

Volumn 250, Issue , 2013, Pages 309-319

  Mishra, N ^a   Sasmal, D ^a   Singh, K K ^b  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

^b BIRSA AGRICULTURAL UNIVERSITY   (India)

Author keywords

amyloid; Acetylcholinesterase inhibitor; Alzheimer's disease; Amnesia; Multi target directed ligand; Scopolamine

Indexed keywords

3 (ANTHRACEN 10 YL) 5 (3 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; DONEPEZIL; NP 9; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL LOSS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; EXPLORATORY RESEARCH; FIBER; IC 50; MALE; MEMORY DISORDER; MOUSE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION;

3-(ANTHRACEN-10-YL)-5-(3-NITROPHENYL)-4,5-DIHYDRO-1H-PYRAZOLE; ACETYLCHOLINESTERASE; ACETYLCHOLINESTERASE INHIBITOR; ACHE; AD; ALZHEIMER'S DISEASE; AMNESIA; AΒ; GLUTATHIONE; GSH; MAO; MONOAMINE OXIDASE; MTDL; MULTI-TARGET-DIRECTED LIGAND; NP-9; PAS; PERIPHERAL ANIONIC SITE; S.E.M.; SCANNING ELECTRON MICROSCOPY; SCOPOLAMINE; TH-T; THIOFLAVIN-T; Β-AMYLOID;

ACETYLCHOLINESTERASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTHRACENES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; GLUTATHIONE; IMMUNOHISTOCHEMISTRY; INDANS; MALE; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE; MICROSCOPY, ELECTRON, SCANNING; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MUSCARINIC ANTAGONISTS; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; PYRAZOLES; SCOPOLAMINE HYDROBROMIDE; TISSUE FIXATION;

EID: 84881643039     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.07.014     Document Type: Article

References (38)

1. Bartolini M., Bertucci C., Cavrini V., Andrisano V. [beta]-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003, 65:407-416.
2. Beeri R., Andres C., Lev-Lehman E., Timberg R., Huberman T., Shani M., Soreq H. Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr Biol 1995, 5:1063-1073.
3. Butterfield D.A. Amyloid beta-peptide 1-42-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr Med Chem 2003, 10:2651-2659.
4. Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008, 51:347-372.
5. Conrad C.D., Lupien S.J., Thanasoulis L.C., McEwen B.S. The effects of type I and type II corticosteroid receptor agonists on exploratory behavior and spatial memory in the Y-maze. Brain Res 1997, 759:76-83.
6. Crouch P.J., Harding S.M.E., White A.R., Camakaris J., Bush A.I., Masters C.L. Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol 2008, 40:181-198.
7. DaSilva K.A., Shaw J.E., McLaurin J.A. Amyloid-β fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 2010, 223:311-321.
8. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 2010, 90:465-494.
9. Dringenberg H.C., Laporte P.P., Diavolitsis P. Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence. Neuroreport 2000, 11:3513-3516.
10. Ebert U., Kirch W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 1998, 28:944-949.
11. Ellman G.L., Courtney K.D. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-90.
12. Estus S., Tucker H.M., van Rooyen C., Wright S., Brigham E.F., Wogulis M., Rydel R.E. Aggregated amyloid-β protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. J Neurosci 1997, 17:7736-7745.
13. Gage G.J., Kipke D.R., Shain W. Whole animal perfusion fixation for rodents 2012, J Vis Exp, JoVE.
14. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 2003, 18:S1-S5.
15. Hersi A.I., Kitaichi K., Srivastava L.K., Gaudreau P., Quirion R. Dopamine D-5 receptor modulates hippocampal acetylcholine release. Mol Brain Res 2000, 76:336-340.
16. Inestrosa N.C., Alvarez A., Pérez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., Garrido J. Acetylcholinesterase accelerates assembly of amyloid-[beta]-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16:881-891.
17. Jhoo J.H., Kim H.C., Nabeshima T., Yamada K., Shin E.J., Jhoo W.K., Kim W., Kang K.S., Jo S.A., Woo J.I. Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res 2004, 155:185-196.
18. Khurana R., Coleman C., Ionescu-Zanetti C., Carter S.A., Krishna V., Grover R.K., Roy R., Singh S. Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 2005, 151:229-238.
19. Laursen S.E., Belknap J. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 1986, 16:355-357.
20. Legault M., Rompré P.P., Wise R.A. Chemical stimulation of the ventral hippocampus elevates nucleus accumbens dopamine by activating dopaminergic neurons of the ventral tegmental area. J Neurosci 2000, 20:1635-1642.
21. Levine H. Thioflavine T interaction with synthetic Alzheimer's disease amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 1993, 2:404-410.
22. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 2007, 6:341-342.
23. Mishra N., Sasmal D. Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation. Bioorg Med Chem Lett 2011, 21:1969-1973.
24. Mishra N., Sasmal D. Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor. Brain Res 2012, 1470:45-51.
25. Mishra N., Sasmal D. Additional acetyl cholinesterase inhibitory property of diaryl pyrazoline derivatives. Bioorg Med Chem Lett 2013, 23:702-705.
26. Mitchell E.S., Hoplight B.J., Lear S.P., Neumaier J.F. BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT< 6< receptor-mediated mechanism. Neuropharmacology 2006, 50:412-420.
27. Okaichi H., Oshima Y., Jarrard L.E. Scopolamine impairs both working and reference memory in rats: a replication and extension. Pharmacol Biochem Behav 1989, 34:599-602.
28. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968, 25:192-205.
29. Takahata K., Minami A., Kusumoto H., Shimazu S., Yoneda F. Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol 2005, 518:140-144.
30. Tariot P.N., Cohen R.M., Sunderland T., Newhouse P.A., Yount D., Mellow A.M., Weingartner H., Mueller E.A., Murphy D.L. l-Deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987, 44:427-433.
31. Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 2000, 21:343-348.
32. Tsunekawa H., Noda Y., Mouri A., Yoneda F., Nabeshima T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav Brain Res 2008, 190:224-232.
33. Ulrich J., Meier-Ruge W., Probst A., Meier E., Ipsen S. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol 1990, 80:624-628.
34. Vogel H.G. Drug discovery and evaluation: pharmacological assays 2008, Springer Verlag, Berlin, Heidelberg, New York.
35. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nature protocols 2006, 1:848-858.
36. Wang Y.J., Zhou H.D., Zhou X.F. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 2006, 11:931-938.
37. Weinreb O., Amit T., Bar-Am O., Youdim B.H., Ladostigil M. A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets 2012, 13:483-494.
38. Yan J.J., Cho J.Y., Kim H.S., Kim K.L., Jung J.S., Huh S.O., Suh H.W., Kim Y.H., Song D.K. Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2009, 133:89-96.